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BACKGROUND. Complete spontaneous regression of melanoma 
metastatic to the lungs is a rare event. 
OBJECTIVE. To report a case of biopsy-proven melanoma meta- 
static to the lung with complete spontaneous regression. 
METHODS. Multidisciplinary case report. 
RESULTS. A 35-year-old white female was diagnosed with met- 
astatic melanoma to the lung. A pleural biopsy confirmed the 
diagnosis. Partial spontaneous regression was noted by a staging 
computed tomography scan prior to enrollment in an investiga- 
tional protocol. Complete spontaneous regression occurred over 
5 months without any form of conventional or alternative ther- 
apy, and the patient remains disease-free 3 years after diagnosis. 
CONCLUSIONS. Our case represents the seventh case of complete 
spontaneous regression of melanoma metastatic to the lung, and 
the only case with histologic confirmation of both the primay 
and pulmona y metastatic lesions. The patient was pregnant 
twice between the time of her initial diagnosis of prima y mel- 
anoma and pulmonary metastatic disease. 0 1998 by the Amer- 
ican Society for Dermatologic Surge y, lnc. Dermatol Surg 
1998;24:915-919. 
pontaneous regression of cancer is defined as 
"the partial or complete disappearance of a ma- S lignant tumor in the absence of all treatment or in 
the presence of therapy which is considered inadequate 
to exert a significant influence on neoplastic disease."' 
Spontaneous regression does not necessarily imply cure 
and need not result in complete disappearance of the 
tumor. Using these criteria, the spontaneous regression 
of cancer has been well described and is widely ac- 
cepted as a rare phen~menon.'-*~ 
Partial spontaneous regression of the primary lesion 
of melanoma is not uncommon, occuring in the range of 
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3-15% of However, complete spontaneous 
regression of the primary lesion is rare and complete 
regression of metastatic lesions even rarer. Partial or 
complete spontaneous regression of metastatic mela- 
noma most often occurs in cutaneous or nodal lesions. 
Herein, we report a case of melanoma metastatic to 
the lungs with subsequent complete spontaneous re- 
gression of the metastatic lesions. This represents the 
seventh case reported in the English language literature 
(Medline) and the first with histologic confirmation of 
the pulmonary metastatic lesions. 
Case Report 
In August 1987, a 29-year-old gravid female noted a 
darkening lesion on the upper back. Biopsy revealed 
melanoma, type unclassified, 1.3 mm in Breslow depth 
extending to the deep margin. The patient underwent 
wide local excision with 4.0 -5.0-cm margins revealing 
scar and inflammation, and no residual melanoma. No 
evidence of regional or distant disease was noted based 
on a thorough history and physical examination. Post- 
partum, following delivery of a healthy baby in 1988, a 
chest x-ray (CXR) revealed no abnormality, and abdom- 
inal ultrasound showed two hepatic hemangiomata 
that were stable from previous exams. The placenta was 
free of melanoma based on histologic and clinical eval- 
uation. 
In November 1992, the patient noted a new left axil- 
lary mass following the uncomplicated birth of her sec- 
ond child. Staging head and body computerized axial 
tomography (CT) scans revealed left axillary lymphad- 
enopathy without evidence of additional disease. Open 
biopsy and subsequent left axillary lymph node dissec- 
tion revealed one of 16 lymph nodes positive for met- 
astatic melanoma. 
In August 1993, the patient noted a new soft tissue 
nodule in the left axillary dissection scar. Fine needle 
aspirate was positive for recurrent melanoma. Head 
and body CT scans demonstrated a tiny left upper lobe 
lung nodule that was too small to characterize and were 
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Figure 1. Contrast enhanced chest CT demonstrates a left upper 
lobe lung nodule (arrow), mediastinal lymph node enlargement, 
and a left pleural effusion (E) .  
Figure 3. Pleural core biopsy demonstrates atypical epithelioid 
cells rompatible with metastatic melanoma W & E ,  x200). 
a marked reduction in the size of the left pleural effu- 
otherwise unremarkable. Wide local excision of the soft 
tissue recurrent disease was performed. 
In November 1993, the patient complained of in- 
creasing left-sided chest pain with pain on inspiration. 
Staging head and body CT scans demonstrated of a 
moderate sized left pleural effusion, a 1.5-cm left upper 
lobe lung nodule, left upper mediastinal, left internal 
mammary, and aorto-pulmonary window lymph node 
enlargement, and a 5 X 6 X 3-cm mass contiguous with 
the gastroesophageal junction and the descending tho- 
racic aorta (Figures 1 and 2). A pleural tap for cytology 
was negative for neoplasm with numerous reactive me- 
sothelial cells. A CT-guided pleural biopsy was then 
performed revealing metastatic melanoma to the lungs 
(Figures 3 and 4). The pleural biopsy was complicated 
by a small pneumothorax that subsequently resolved. 
In December 1993, the patient elected to enroll in an 
investigational protocol for stage IV melanoma. Prior to 
therapy, repeat head and body CT scans demonstrated 
sion and mediastinal lymph node enlargement with 
complete resolution of the left upper lobe lung nodule 
(Figure 5) with no other evidence of distant disease. The 
residual posterior mediastinal mass now measured 4 X 
4 X 1.5 cm (Figure 6). Because of the observed improve- 
ment in the absence of treatment, the patient was not 
enrolled into the protocol. Follow-up CT scans in Feb- 
ruary 1994 showed continued improvement. A com- 
plete response with no evidence of disease was noted 
on chest CT scan in May 1994 (Figure 7). No further 
therapy was instituted and the patient remains free of 
disease 9 years after the initial diagnosis of melanoma 
and 4.5 years after the diagnosis of metastatic disease. 
The most recent CT scan in October 1996 and CXR in 
January 1997 demonstrated no evidence of recurrence. 
To date the patient has received no systemic therapy for 
her disease. Of note, specific detailed questioning re- 
vealed no change in diet, lifestyle, activity, or ”alterna- 
tive therapy.” 
Figure 4. SlOO protein immunoperoxidase stain decorates the 
atypical malignant cells confirming a diagnosis of metastatic 
melanoma (X400). 
Figure 2. Contrast enhanced CT demonstrates a mass (M) 
contiguous with the gastroesophageal (GE) junction. 
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Figure 5. Spontaneous regression of left upper lobe lung nodule 
with minimal residual mediastinal lymph node enlargement 
(arrow) is noted on this follow up chest CT obtained 1 month 
later. Note also improvement in left pleural effusion. 
Discussion 
Spontaneous regression of metastatic melanoma is a 
rare event, reported as occurring in approximately 
0.22-0.27% of cases.4,9,12,16,17 The complete spontaneous 
regression of metastatic melanoma was first reported in 
1889 by Bennett.3 In 1979, Bodurtha reviewed 29 cases 
of spontaneous regression in metastatic me lan~ma .~ ,~  
Of these, 26 had regression of cutaneous and/or lym- 
phatic nodal metastases and five had regression of ra- 
diographically demonstrated pulmonary metastases. In 
1986, Mikhail and Gorsulowsky reported one addi- 
tional case of spontaneous regression of metastatic mel- 
anoma to the lungs.” The present case represents the 
seventh report of complete spontaneous regression of 
melanoma with metastasis to the lungs and the first in 
the English language literature with histologic confir- 
mation of pulmonary involvement (Medline). When 
evaluating cases of spontaneous regression in meta- 
Figure 6. Mass ( m )  contiguous with GE junction is also 
smaller. 
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Figure 7. Complete resolution of left pleural effusion, 
mediastinal lymph node enlargement and mass contiguous with 
GE junction respectively is noted on this follow up CT obtained 
approximately 5 months after CT demonstrating metastatic 
disease. 
static melanoma, histologic confirmation of the sus- 
pected lesion may be important due to the fact that 
open thoracotomy on patients with melanoma and ra- 
diographic lesions suspicious for pulmonary metastasis 
shows benign or unrelated disease in nearly one-third 
of cases?’ 
The single most important predictor of prognosis 
and risk of metastasis is the primary tumor thickness 
measured in millimeters (Breslow depth).” While mel- 
anoma can metastasize to any organ, the most common 
sites of metastasis are the skin and subcutaneous tissue 
and lymph nodesz1 The most common visceral sites of 
metastasis are, in order of decreasing frequency, the 
lung, liver, brain, bone, and gastrointestinal 
Given the relative frequency of pulmonary metastatic 
melanoma, the occurrence of spontaneous regression in 
these lesions based on reports in the literature must be 
rare indeed. Patients with pulmonary metastasis have 
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an overall 5-year survival of approximately 4% and a 
median life expectancy of 6-7 months.25 
A number of observations have stimulated interest in 
the role of pregnancy and melanoma. While controver- 
sial, most studies regarding prognosis of pregnancy- 
associated melanoma suggest a possible decreased dis- 
ease-free interval but no effect on overall survival when 
controlling for tumor thickness and stage of dis- 
A waiting time of 0-5 years to become preg- 
nant after the diagnosis of melanoma is recommended 
depending on tumor thickness, stage of disease, patient 
age, and desire to get pregnant. Definitive answers to 
how pregnancy affects melanoma, if at all, remain un- 
clear. 
The mechanisms involved in the spontaneous regres- 
sion of primary and metastatic melanoma are unknown 
but may be related to immunologic, endocrine, meta- 
bolic, hormonal, and nutritional  factor^.^-^'*'^ Alter- 
ations in immunity following infection, acute inflam- 
mation, or incomplete excision have been proposed as 
mediating factors. Postoperative infection did not occur 
in our patient, however, alterations in immunity sec- 
ondary to inflammation following a pneumothorax 
may have influenced her complete spontaneous regres- 
sion of biopsy-proven pulmonary metastatic mela- 
noma. 
Over the last 5 years, immunological studies of pa- 
tients with melanoma have revealed that many have 
cytotoxic T cell (CTL) responses to antigens that are 
present on melanoma cells. In patients treated with 
adoptive transfer of tumor-infiltrating lymphocytes, the 
presence of CTL reactive against gp100-derived 
epitopes has been correlated with favorable clinical re- 
sponse; these CTL may account for the mechanism of 
tumor regression in some patients who respond to in- 
terleukin-2 (IL-2)-based therapies.35 Some of these and 
other defined melanoma antigens are also present on 
normal cells of melanocytic origin, and patients who 
respond to IL-2 therapy often develop patchy vitiligo. 
Our patient did not develop vitiligo. We lacked a source 
of fresh autologous tumor after our patient went into 
remission and could not test her for the presence of CTL 
responses to autologous tumor. We obtained peripheral 
blood from the patient after her complete remission in 
hopes that we could determine the presence of CTL 
responses to defined HLA-A2-associated melanoma 
peptides such as those derived from MART-1/ 
Melan-A, tyrosinase, and gp100.36-49 Unfortunately, 
the patient’s HLA type was HLA-A26, B18, B38, and to 
date, there are no defined epitopes for melanoma-reac- 
tive CTL associated with any of these MHC molecules. 
We plan to look for evidence of CTL responses in this 
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